Previously, it has been also reported that short-term treatment with an anti-PrP antibody, 6D11, in AD model APP/PS1 mice can dramatically reverse behavioral deficits without affecting the amyloid burden by blocking the Aβo/PrPC interaction (Chung et al., 2010). Here, ABO is linked to Alzheimer disease.